Expertise in
13
conditions

Dr. Wade T. Iams

Tennessee Oncology PLLC
Nashville, TN
Expertise in
13
conditions
Specialties:Hematology Oncology | Hematology | Oncology
Accepting New Patients
Offers Telehealth
Expertise in
13
conditions
OverviewInsuranceLocationsClinical Research

Overview

Wade Iams is a Hematologist Oncology specialist and a Hematologist in Nashville, Tennessee. Dr. Iams is highly rated in 13 conditions, according to our data. His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and EGFR Positive Lung Cancer. Dr. Iams is currently accepting new patients.

His clinical research consists of co-authoring 76 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Hospital Affiliations
Vanderbilt University Medical Center
Languages Spoken
English
Spanish
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Cigna
  •  Blue Cross Blue Shield
  •  Alliant Health
  •  Oscar
  •  Humana

Locations

TENNESSEE ONCOLOGY PLLC
4220 Harding Pike, Nashville, TN 37205
615-385-3751

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

An Adaptive Phase III, Multicenter, Randomized, Open-Label, Controlled Study of M7824 (Bintrafusp Alfa) Versus Pembrolizumab as a First-line Treatment in Patients With PD-L1 Expressing Advanced Non-small Cell Lung Cancer
An Adaptive Phase III, Multicenter, Randomized, Open-Label, Controlled Study of M7824 (Bintrafusp Alfa) Versus Pembrolizumab as a First-line Treatment in Patients With PD-L1 Expressing Advanced Non-small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: August 13, 2024
Intervention Type: Drug
Study Drugs: M7824, Pembrolizumab
Study Phase: Phase 3
A Phase I/Ib Open-Label, Multi-Center, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics and Preliminary Efficacy of Intravenous NBF 006 in Patients With Non-Small Cell Lung, Pancreatic, or Colorectal Cancer Followed by a Dose Expansion Study in Patients With KRAS-Mutated Non-Small Cell Lung Cancer
A Phase I/Ib Open-Label, Multi-Center, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics and Preliminary Efficacy of Intravenous NBF 006 in Patients With Non-Small Cell Lung, Pancreatic, or Colorectal Cancer Followed by a Dose Expansion Study in Patients With KRAS-Mutated Non-Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: July 24, 2024
Intervention Type: Drug
Study Drug: NBF-006
Study Phase: Phase 1
An Open-label, Phase 1, Dose-escalation Study to Evaluate the Safety and Preliminary Antitumor Activity of TAK-676 With Pembrolizumab Following Radiation Therapy in the Treatment of Non-small-cell Lung Cancer, Triple-negative Breast Cancer, or Squamous-cell Carcinoma of the Head and Neck That Has Progressed on Checkpoint Inhibitors
An Open-label, Phase 1, Dose-escalation Study to Evaluate the Safety and Preliminary Antitumor Activity of TAK-676 With Pembrolizumab Following Radiation Therapy in the Treatment of Non-small-cell Lung Cancer, Triple-negative Breast Cancer, or Squamous-cell Carcinoma of the Head and Neck That Has Progressed on Checkpoint Inhibitors
Enrollment Status: Completed
Publish Date: June 11, 2024
Intervention Type: Drug, Radiation
Study Drugs: Pembrolizumab, TAK-676
Study Phase: Phase 1
A Phase 1, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of SQZ-PBMC-HPV as Monotherapy and in Combination With Atezolizumab or Other Immune Checkpoint Inhibitors in HLA-A*02+ Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
A Phase 1, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of SQZ-PBMC-HPV as Monotherapy and in Combination With Atezolizumab or Other Immune Checkpoint Inhibitors in HLA-A*02+ Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
Enrollment Status: Completed
Publish Date: April 14, 2023
Intervention Type: Drug, Biological
Study Drugs: SQZ-PBMC-HPV, Atezolizumab, Ipilimumab, Nivolumab
Study Phase: Phase 1
A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination With Avelumab With and Without Palliative Radiotherapy in Participants With Selected Advanced Solid Tumors
A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination With Avelumab With and Without Palliative Radiotherapy in Participants With Selected Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: November 30, 2022
Intervention Type: Drug, Radiation
Study Phase: Phase 1
View 4 Less Clinical Trials

71 Total Publications

A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6-Targeting Antibody-Drug Conjugate, in Patients With Small Cell Lung Cancer.
A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6-Targeting Antibody-Drug Conjugate, in Patients With Small Cell Lung Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 24, 2024
Similar Doctors
Expertise in
18
conditions
Dr. Brian I. Rini
Hematology Oncology | Oncology | Hematology
Expertise in
18
conditions
Dr. Brian I. Rini
Hematology Oncology | Oncology | Hematology

Vanderbilt Health Clinicians, LLC

3601 The Vanderbilt Clinic, 
Nashville, TN 
 (2.5 mi)
615-322-3000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Brian Rini is a Hematologist Oncology specialist and an Oncologist in Nashville, Tennessee. Dr. Rini is highly rated in 18 conditions, according to our data. His top areas of expertise are Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, WT1-Related Wilms Tumor Syndromes, Wilms Tumor, and Nephrectomy. Dr. Rini is currently accepting new patients.

Expertise in
38
conditions
Dr. Nishitha M. Reddy
Hematology Oncology | Oncology | Hematology
Expertise in
38
conditions
Dr. Nishitha M. Reddy
Hematology Oncology | Oncology | Hematology

Vanderbilt Health Clinicians, LLC

3601 The Vanderbilt Clinic, 
Nashville, TN 
 (2.5 mi)
615-322-3000
Languages Spoken:
English, Hindi, Spanish, Telugu
See accepted insurances
Accepting New Patients
Offers Telehealth

Nishitha Reddy is a Hematologist Oncology specialist and an Oncologist in Nashville, Tennessee. Dr. Reddy is highly rated in 38 conditions, according to our data. Her top areas of expertise are Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Reddy is currently accepting new patients.

Bipin N. Savani
Expertise in
26
conditions
Dr. Bipin N. Savani
Hematology Oncology | Transplant Surgery | Hematology
Expertise in
26
conditions
Dr. Bipin N. Savani
Hematology Oncology | Transplant Surgery | Hematology

Vanderbilt Health Clinicians, LLC

3601 The Vanderbilt Clinic, 
Nashville, TN 
 (2.5 mi)
615-322-3000
Experience:
36+ years
Languages Spoken:
English, Arabic, Hindi
See accepted insurances
Accepting New Patients
Offers Telehealth

Bipin Savani is a Hematologist Oncology specialist and a Transplant Surgeon in Nashville, Tennessee. Dr. Savani has been practicing medicine for over 36 years is highly rated in 26 conditions, according to our data. His top areas of expertise are Acute Myeloid Leukemia (AML), Graft Versus Host Disease (GvHD), Leukemia, Bone Marrow Transplant, and Bone Graft. Dr. Savani is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile